Therapy News and Research

RSS

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Strength training exercise program for seniors provides sustained cognitive, economic benefits

A one-year follow-up study on seniors who participated in a strength training exercise program shows sustained cognitive benefits as well as savings for the healthcare system. The research, conducted at the Centre for Hip Health and Mobility at Vancouver Coastal Health and the University of British Columbia, is published today in the Archives of Internal Medicine.

14 Dec 2010

Rheumatologists raise awareness on early diagnosis and treatment of inflammatory arthritis

In people who develop symptoms of inflammatory arthritis, early diagnosis and treatment can have a significant impact on the course of disease—in some cases even preventing deformity and loss of function from rheumatoid arthritis, according to an article in the December issue of JCR: Journal of Clinical Rheumatology.

14 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.

14 Dec 2010

Lack of 'systematic reviews' in stroke research lead to waste of time, resources

Research being conducted into stroke needs to slow down and take stock if a therapeutic breakthrough is ever likely to happen, says a leading stroke expert.

14 Dec 2010

Gore releases statement in response to safety of GORE HELEX Septal Occluder for PFO closure in cryptogenic stroke patients

W. L. Gore & Associates (Gore) today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.

14 Dec 2010

EHSI negotiates potential option agreement with Regenetech for Rotary Cell Culture System

Emerging Healthcare Solutions, Inc. is negotiating a potential option agreement with biotech firm Regenetech, Inc.

14 Dec 2010

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

WebPT announces closing of Series A funding round

WebPT, a Web-based electronic medical records system (EMR) for physical therapists, today announces it has closed a Series A funding round totaling $1 million in private equity funding. The company has very quickly become the fastest-growing Web-based documentation software now used by more than 5,000 physical therapists in just three years.

14 Dec 2010

Beta-catenin protein plays a key role in development of stem cells in acute leukaemia

Researchers at King's College London have discovered that leukaemic stem cells can be reversed to a pre-leukaemic stage by suppressing a protein called beta-catenin found in the blood.

14 Dec 2010

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

14 Dec 2010

Osteoporosis drug reduces bone loss in oral cancer

A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.

14 Dec 2010

Senator Leahy calls for U.S. to suspend direct aid to Haiti's government, visas for Haitian officials

Senator Patrick Leahy (D-Vt.), who chairs the Senate Appropriations Committee's Subcommittee on the State, Foreign Operations, and Related Programs, "on Friday urged President Barack Obama's administration to suspend direct aid to Haiti's government and visas for its top officials until it ensures a fair and democratic outcome to disputed national elections," Reuters reports.

14 Dec 2010

Drug to reverse immunological decline in aging

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.

14 Dec 2010

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.

14 Dec 2010

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

14 Dec 2010

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer™ technology.

13 Dec 2010

Therapy News and Research

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Strength training exercise program for seniors provides sustained cognitive, economic benefits

Rheumatologists raise awareness on early diagnosis and treatment of inflammatory arthritis

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

Lack of 'systematic reviews' in stroke research lead to waste of time, resources

Gore releases statement in response to safety of GORE HELEX Septal Occluder for PFO closure in cryptogenic stroke patients

EHSI negotiates potential option agreement with Regenetech for Rotary Cell Culture System

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

WebPT announces closing of Series A funding round

Beta-catenin protein plays a key role in development of stem cells in acute leukaemia

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

Osteoporosis drug reduces bone loss in oral cancer

Senator Leahy calls for U.S. to suspend direct aid to Haiti's government, visas for Haitian officials

Drug to reverse immunological decline in aging

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

Majority of brain tumor patients use alternative therapies

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News